MIJ is pleased to announce that we have recently invested in the series B round of IgGenix Inc..

IgGenix is a privately held antibody discovery and development company taking a revolutionary approach to address allergies and atopic diseases.

This financing round was co-led by Alexandria Venture Investments and includes new investor Eli Lilly and Company, as well as existing investors Khosla Ventures, Sean Parker, AllerFund and others.

Sep.2,2025, IgGenix Announced Completion of Enrollment for Phase 1 Clinical Trial “ACCELERATE Peanut” with IGNX001 in Peanut Allergy